Xoma Royalty Corporation (XOMA)

$35.17 +0.90 (2.63%)
Market Cap 414.26M
Revenue (ttm) 28.49M
Net Income (ttm) -13.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 38.49
Profit Margin -48.51%
Debt to Equity Ratio 1.23
Volume 31,300
Avg Vol 54,038
Day's Range N/A - N/A
Shares Out 12.09M
Stochastic %K 36%
Beta 1.02
Analysts Strong Sell
Price Target $69.67

Company Profile

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 204 7200
Address:
2200 Powell Street, Suite 310, EmeryVille, United States
Mergerbrief
Mergerbrief Oct. 24 at 11:56 AM
$MURA / $XOMA - Shareholder Vote $MURA MergerBrief.com For Full Schedule
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 17 at 6:45 PM
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty $LVTX $XOMA https://stocktwits.com/news/equity/markets/lava-therapeutics-stock-drops-after-amended-deal-with-xoma-royalty/ch6sjlqR3o3
0 · Reply
jigjagTwits
jigjagTwits Oct. 10 at 7:58 PM
$XOMA
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 4 at 10:21 PM
The attachment compares the projected revenue & EPS multiples of $LGND v. 3 peers $RPRX $XNCR $XOMA that also invest in biopharma royalties. LGND appears to be an amazing company with a great future. We are not bashing LGND. However, simple analytics suggest LGND, up ~80%+ since June 2025, is now over-priced primarily because they trade @ multiples 2X higher than these 3 peers. Of course we could be wrong. This is not investment advice. Shorting a stock like LGND is extremely risky because, in theory, losses are infinite. History suggests LGND might retract after reporting Q3 2025 earnings as valuation opportunity are reset (the $HROW phenomenon in May 2023...but HROW recovered & then some later). LGND also holds equity investments where valuation gains may not manifest in traditional revenues & earnings forecasts. Again, this is not investment advice. Comments? Pushback? Are these 3 not peers?
2 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Oct. 2 at 8:56 PM
$XOMA
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 30 at 11:33 AM
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting $LVTX $XOMA https://stocktwits.com/news/equity/markets/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN
0 · Reply
TwongStocks
TwongStocks Sep. 23 at 12:20 PM
$XOMA Insightful article that explains XOMA's current strategy https://www.biopharmadive.com/news/xoma-royalty-zombie-biotechs-liquidate-wind-down/760535/
0 · Reply
rmelandri1
rmelandri1 Sep. 20 at 9:14 AM
$XOMA Added
0 · Reply
TwongStocks
TwongStocks Sep. 17 at 1:05 PM
$XOMA closes tender offer for $HLVX https://www.globenewswire.com/news-release/2025/09/17/3151655/7281/en/XOMA-Royalty-Announces-Closing-of-Tender-Offer-for-HilleVax-Inc.html • Following the closing of the tender offer, XOMA acquired HLVX • HLVX shareholders will receive $1.95 and a CVR per share.
0 · Reply
biotechbuyside
biotechbuyside Sep. 16 at 2:23 PM
$EPIX Essa keeps sliding but the story hasn’t changed — $1.69/share already returned (80M+ back), still sitting on cash + XenoTherapeutics deal lined up w/ $XOMA backing. Vote now Sept 29 while terms get cleaned up. Way oversold down here. Street still pointing $2 tgt (+700-800%). Risk/reward setup 🔥. Lots of faith in CEO David Parkinson @RegulaRandy @dindinn @Succosesteve35 @Tra123842 @drsych @bigirishyeti @marvinash @Biotech_Multibaggers @Stocks4thought @Cat_in_hat
0 · Reply
Latest News on XOMA
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

Oct 17, 2025, 11:45 AM EDT - 8 days ago

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

XOMA Royalty PFD Update: Going Back To My Original Sell Ratings

Oct 3, 2025, 8:00 AM EDT - 22 days ago

XOMA Royalty PFD Update: Going Back To My Original Sell Ratings

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

Oct 2, 2025, 4:43 PM EDT - 23 days ago

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

Sep 24, 2025, 6:00 AM EDT - 4 weeks ago

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

EPIX

XOMA Royalty Declares Quarterly Preferred Stock Dividends

Sep 22, 2025, 7:30 AM EDT - 4 weeks ago

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

Sep 17, 2025, 9:00 AM EDT - 5 weeks ago

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 7 weeks ago

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Aug 20, 2025, 8:49 AM EDT - 2 months ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Aug 13, 2025, 7:30 AM EDT - 2 months ago

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

Aug 5, 2025, 9:20 PM EDT - 2 months ago

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

HLVX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

Aug 5, 2025, 6:01 PM EDT - 2 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

HLVX

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

Aug 4, 2025, 7:30 AM EDT - 2 months ago

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

Jul 14, 2025, 8:00 AM EDT - 3 months ago

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

EPIX

Collect Up To 11.5% From The Healthcare Sector

Jul 6, 2025, 10:15 AM EDT - 3 months ago

Collect Up To 11.5% From The Healthcare Sector

THQ

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

Jun 27, 2025, 7:30 AM EDT - 4 months ago

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025, 8:01 AM EDT - 5 months ago

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 7:30 AM EDT - 6 months ago

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

Apr 14, 2025, 7:30 AM EDT - 6 months ago

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

Apr 8, 2025, 7:15 AM EDT - 7 months ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

TAK

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

Apr 8, 2025, 12:24 AM EDT - 7 months ago

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

Apr 2, 2025, 7:30 AM EDT - 7 months ago

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Mar 17, 2025, 4:30 PM EDT - 7 months ago

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Feb 25, 2025, 7:00 AM EST - 8 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

XOMA Royalty to Present at Investor Conferences in March

Feb 24, 2025, 4:05 PM EST - 8 months ago

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 9 months ago

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Nov 7, 2024, 7:30 AM EST - 1 year ago

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Oct 22, 2024, 8:00 AM EDT - 1 year ago

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

TWST

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15, 2024, 10:31 AM EDT - 1 year ago

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 1 year ago

I Am Banking On The Silver Tsunami With Big Dividends

HROW THQ

XOMA Stock Dips Amidst Biotech Sector Decline

Oct 3, 2024, 3:53 PM EDT - 1 year ago

XOMA Stock Dips Amidst Biotech Sector Decline

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

Sep 23, 2024, 6:30 AM EDT - 1 year ago

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty to Present at Upcoming Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 1 year ago

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Aug 13, 2024, 7:30 AM EDT - 1 year ago

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

My 2 Top Royalty Income Picks, Yields Up To 9.5%

Jul 19, 2024, 8:30 AM EDT - 1 year ago

My 2 Top Royalty Income Picks, Yields Up To 9.5%

KRP

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29, 2024, 2:31 AM EDT - 1 year ago

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

XOMA Declares Quarterly Preferred Stock Dividends

Jun 20, 2024, 7:30 AM EDT - 1 year ago

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

Jun 12, 2024, 7:30 AM EDT - 1 year ago

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

Jun 3, 2024, 7:45 PM EDT - 1 year ago

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

May 14, 2024, 7:30 AM EDT - 1 year ago

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

May 9, 2024, 7:30 AM EDT - 1 year ago

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Apr 25, 2024, 7:30 AM EDT - 1 year ago

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB PGEN

XOMA Corporation Announces Closing of Tender Offer

Apr 3, 2024, 9:00 AM EDT - 1 year ago

XOMA Corporation Announces Closing of Tender Offer

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Mar 19, 2024, 4:05 PM EDT - 1 year ago

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Mar 13, 2024, 11:49 AM EDT - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Mar 8, 2024, 7:30 AM EST - 1 year ago

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

XOMA to Present at Upcoming Investor Conferences in March

Feb 28, 2024, 7:30 AM EST - 1 year ago

XOMA to Present at Upcoming Investor Conferences in March

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Feb 19, 2024, 11:03 AM EST - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Feb 16, 2024, 8:00 AM EST - 1 year ago

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Mergerbrief
Mergerbrief Oct. 24 at 11:56 AM
$MURA / $XOMA - Shareholder Vote $MURA MergerBrief.com For Full Schedule
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 17 at 6:45 PM
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty $LVTX $XOMA https://stocktwits.com/news/equity/markets/lava-therapeutics-stock-drops-after-amended-deal-with-xoma-royalty/ch6sjlqR3o3
0 · Reply
jigjagTwits
jigjagTwits Oct. 10 at 7:58 PM
$XOMA
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 4 at 10:21 PM
The attachment compares the projected revenue & EPS multiples of $LGND v. 3 peers $RPRX $XNCR $XOMA that also invest in biopharma royalties. LGND appears to be an amazing company with a great future. We are not bashing LGND. However, simple analytics suggest LGND, up ~80%+ since June 2025, is now over-priced primarily because they trade @ multiples 2X higher than these 3 peers. Of course we could be wrong. This is not investment advice. Shorting a stock like LGND is extremely risky because, in theory, losses are infinite. History suggests LGND might retract after reporting Q3 2025 earnings as valuation opportunity are reset (the $HROW phenomenon in May 2023...but HROW recovered & then some later). LGND also holds equity investments where valuation gains may not manifest in traditional revenues & earnings forecasts. Again, this is not investment advice. Comments? Pushback? Are these 3 not peers?
2 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Oct. 2 at 8:56 PM
$XOMA
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 30 at 11:33 AM
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting $LVTX $XOMA https://stocktwits.com/news/equity/markets/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN
0 · Reply
TwongStocks
TwongStocks Sep. 23 at 12:20 PM
$XOMA Insightful article that explains XOMA's current strategy https://www.biopharmadive.com/news/xoma-royalty-zombie-biotechs-liquidate-wind-down/760535/
0 · Reply
rmelandri1
rmelandri1 Sep. 20 at 9:14 AM
$XOMA Added
0 · Reply
TwongStocks
TwongStocks Sep. 17 at 1:05 PM
$XOMA closes tender offer for $HLVX https://www.globenewswire.com/news-release/2025/09/17/3151655/7281/en/XOMA-Royalty-Announces-Closing-of-Tender-Offer-for-HilleVax-Inc.html • Following the closing of the tender offer, XOMA acquired HLVX • HLVX shareholders will receive $1.95 and a CVR per share.
0 · Reply
biotechbuyside
biotechbuyside Sep. 16 at 2:23 PM
$EPIX Essa keeps sliding but the story hasn’t changed — $1.69/share already returned (80M+ back), still sitting on cash + XenoTherapeutics deal lined up w/ $XOMA backing. Vote now Sept 29 while terms get cleaned up. Way oversold down here. Street still pointing $2 tgt (+700-800%). Risk/reward setup 🔥. Lots of faith in CEO David Parkinson @RegulaRandy @dindinn @Succosesteve35 @Tra123842 @drsych @bigirishyeti @marvinash @Biotech_Multibaggers @Stocks4thought @Cat_in_hat
0 · Reply
biotechbuyside
biotechbuyside Sep. 15 at 4:19 PM
$EPIX Even after the $1.69/share payout (80 stacks back to shareholders), they’ve still got cash + a buyout with XenoTherapeutics (backed by $XOMA). Shareholder vote pushed to Sept 29 as deal terms get fine-tuned. Stock way oversold, analysts still see $2.00 tgt (+700-800%). Setup’s wild. @RegulaRandy @dindinn @Succosesteve35 @Tra123842 @drsych @bigirishyeti @marvinash @Biotech_Multibaggers @Stocks4thought @Cat_in_hat VERY VERY
0 · Reply
Mergerbrief
Mergerbrief Sep. 15 at 11:54 AM
$HLVX / $XOMA - Tender Offer Expires MergerBrief.com
0 · Reply
TwongStocks
TwongStocks Sep. 12 at 1:47 PM
$HLVX NASDAQ Equity Corporate Actions Alert # 2025 - 503 Information Regarding the Tender Offer of HilleVax, Inc. (HLVX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-503 The tender offer by $XOMA to acquire all of the outstanding common stock of HilleVax, Inc. (HLVX) is scheduled to expire one minute after 11:59 p.m. ET, on September 15, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 17, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 16, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (September 17) and will be suspended effective September 18, 2025. Tender offer: HLVX shareholders will receive $1.95 plus one non-transferable contingent value right for each share held. If you own 1000 HLVX, you will receive $1950 plus 1000 CVRs.
0 · Reply
fantastex
fantastex Aug. 27 at 11:56 AM
$EPIX dont trust any paid basher here. Do your DD. Still 0.22$ or capital to distribute+ 0.06$ per CVR + buyout price to be paid for a company with still $32M cash on hand. Deal backed by $XOMA this will be valued 0.50-0.70$ next week.
0 · Reply
Sswerve
Sswerve Aug. 20 at 7:47 PM
$MURA Congrats to the clowns who bought this over $2 . You are the proud new owners of $XOMA another failed biotech that’s down 99% since IPO. 😂🤣🤣. Tried to warn you clowns you were falling for an Irish scam. Closed out my short last week , just had to rub it in for the dudes who were calling me low IQ and retarded🤡🤡
1 · Reply
inelegantinvest
inelegantinvest Aug. 20 at 7:28 PM
Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA
0 · Reply
inelegantinvest
inelegantinvest Aug. 20 at 7:23 PM
Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA
0 · Reply
topstockalerts
topstockalerts Aug. 20 at 1:44 PM
$XOMA she wants to move higher..
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 20 at 12:52 PM
Mural Oncology To Be Acquired By Xoma Royalty $MURA $XOMA https://stocktwits.com/news/equity/markets/mural-oncology-to-be-acquired-by-xoma-royalty/chsioLsRdhL
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 20 at 12:37 PM
$MURA (halted pre) 98% Premium: $XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal https://ooc.bz/l/74570
0 · Reply
TwongStocks
TwongStocks Aug. 20 at 12:32 PM
$MURA Enters Agreement to be Acquired by $XOMA https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp Base amount is $2.035 per share. Shareholders may receive an additional cash amount per share of up to $0.205 per share, which would be calculated on the basis of the amount by which Mural’s Closing Net Cash on the Closing Net Cash Date exceeds its Estimated Closing Net Cash.
0 · Reply
SEVENXStheGOAT
SEVENXStheGOAT Aug. 20 at 12:31 PM
$MURA to be Acquired by XRA 5 Corp, a wholly owned subsidiary of $XOMA for between $2.035 and $2.24 in Cash per Share
0 · Reply